- Medtronic (NYSE:MDT) reported new 24‑month TITAN 2 data for its Altaviva implantable tibial neuromodulation device in urge urinary incontinence.
- The TITAN 2 study update highlighted sustained symptom control and quality of life benefits for patients through two years of follow up.
- Medtronic also launched the ENDURANCE real world program to track longer term Altaviva outcomes in routine clinical practice.
- The fresh TITAN 2 and ENDURANCE evidence for Altaviva deserves to be weighed alongside the rest of our Medtronic findings. Check out 5 other big wins that Medtronic investors should know about.
For a wider angle on how device makers and data focused platforms are reshaping care, compare this news with picks in 33 healthcare AI stocks.
Medtronic, a US based medical equipment group with a market cap of about $117.6b, builds device based therapies that hospitals and clinicians use for long term disease management. Extended data on Altaviva fits directly into how the business positions its neuromodulation portfolio with urology specialists.
See how Medtronic's balance sheet measures up.
Medtronic’s Altaviva data backs the higher margin therapy tilt, not just a single product win
The fresh Altaviva results mainly speak to Medtronic’s broader narrative about leaning into higher vitality therapies. Long term symptom control and quality of life gains line up with the pelvic health angle already flagged alongside Symplicity and Cardiac Ablation Solutions in the analyst view. For investors, the signal is less about one urology device and more about whether Medtronic can keep shifting its mix toward therapies that support the targeted margin uplift after the MiniMed separation and design to cost programs.
See how these catalysts shape Medtronic's path to a $105 fair value.
The clearest proof point to watch from here is how Altaviva contributes in the upcoming ENDURANCE real world readouts. This includes persistence on therapy and procedure adoption across the 170 patient, 30 center program that runs over the next five years. Weak usage patterns there would undercut the idea that pelvic neuromodulation is a durable earnings driver for Medtronic rather than a niche add on.
Add Medtronic to your Watchlist and get alerts as these catalysts play out.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com